{"organizations": [], "uuid": "85dbbc3b002608d61d8939b675897dc4ae3ad8dc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180111.html", "section_title": "Archive News &amp; Video for Thursday, 11 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nanobiotix-partners-with-the-provi/brief-nanobiotix-partners-with-the-providence-cancer-institute-to-run-immunotherapeutic-preclinical-research-in-pancreatic-cancers-idUSFWN1P6011", "country": "US", "domain_rank": 408, "title": "BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.83, "site_type": "news", "published": "2018-01-11T15:47:00.000+02:00", "replies_count": 0, "uuid": "85dbbc3b002608d61d8939b675897dc4ae3ad8dc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nanobiotix-partners-with-the-provi/brief-nanobiotix-partners-with-the-providence-cancer-institute-to-run-immunotherapeutic-preclinical-research-in-pancreatic-cancers-idUSFWN1P6011", "ord_in_thread": 0, "title": "BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers", "locations": [], "entities": {"persons": [{"name": "nanobiotix", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "providence cancer institute to run immunotherapeutic preclinical research in pancreatic cancers", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 11 (Reuters) - NANOBIOTIX SA:\n* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS\n* COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR * WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.\n* HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-11T15:47:00.000+02:00", "crawled": "2018-01-12T18:43:19.000+02:00", "highlightTitle": ""}